Programa de Pós-Graduação em Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitória, Brazil.
Healthcare-Associated Infection, Fungal, Antimicrobial Resistance, Antimicrobial Use, and Sepsis Division, United Kingdom Health Security Agency, London, UK.
Int J Dermatol. 2022 Dec;61(12):1506-1510. doi: 10.1111/ijd.16319. Epub 2022 Jul 1.
The implications of COVID-19 co-infection in patients under treatment for Hansen's disease (HD, leprosy) remain uncertain. We aimed to describe clinical characteristics, treatments, and outcomes in patients with HD and COVID-19 in Brazil.
Cross-sectional study recruiting adult HD patients with PCR-confirmed COVID-19 from five HD treatment centers in Brazil between March 1, 2020, and March 31, 2021. At the time of this study, no patient had received COVID-19 vaccine.
Of 1377 patients under treatment for HD, 70 (5.1%) were diagnosed with COVID-19. Of these, 41 (58.6%) had PCR-confirmed COVID-19, comprising 19 men and 22 women, aged 24-67 (median 45) years. HD was multibacillary in 39/41 patients. Eight patients ceased WHO Multi-Drug Therapy for HD, three for lack of drugs, two because of COVID-19, and three for other reasons. Of the 33 who continued treatment, 26 were on the standard regimen and seven an alternative regimen. Seventeen patients were receiving oral prednisone, including nine patients with type 1 reaction, four with type 2 reaction, three with neuritis, and one with rheumatologic disease. Twelve patients were hospitalized for COVID-19, and six patients died, of whom three had hypertension and one also had type 2 diabetes and obesity.
COVID-19 and Hansen's disease co-infection did not appear to change the clinical picture of either disease in this cross-sectional study. The wider impact of the pandemic on persons affected by HD requires follow-up and monitoring.
COVID-19 与正在接受治疗的麻风病（HD，麻风病）患者合并感染的影响仍不确定。我们旨在描述巴西 HD 患者合并 COVID-19 的临床特征、治疗方法和结局。
这是一项横断面研究，招募了 2020 年 3 月 1 日至 2021 年 3 月 31 日期间巴西五个 HD 治疗中心的经 PCR 确诊的 COVID-19 成年 HD 患者。在本研究时，尚无患者接种 COVID-19 疫苗。
在 1377 名接受 HD 治疗的患者中，有 70 名（5.1%）被诊断患有 COVID-19。其中 41 名（58.6%）的 PCR 确诊为 COVID-19，包括 19 名男性和 22 名女性，年龄 24-67 岁（中位数 45 岁）。39/41 例 HD 为多菌型。8 名患者停止了世卫组织的 HD 多药治疗，3 名因缺乏药物，2 名因 COVID-19，3 名因其他原因。在继续治疗的 33 名患者中，26 名患者接受了标准治疗方案，7 名患者接受了替代治疗方案。17 名患者正在接受口服泼尼松治疗，其中 9 名患者出现 1 型反应，4 名患者出现 2 型反应，3 名患者出现神经炎，1 名患者出现风湿性疾病。12 名患者因 COVID-19 住院，6 名患者死亡，其中 3 名患者患有高血压，1 名患者还患有 2 型糖尿病和肥胖症。
在这项横断面研究中，COVID-19 与 HD 合并感染似乎并未改变两种疾病的临床特征。大流行对受 HD 影响的人群的更广泛影响需要随访和监测。
